Epilepsy News

The FDA has granted orphan drug designation to a microbiome-modifying biologic to treat Angelman syndrome, according to the manufacturer.

Among adolescents with focal epilepsy, nonmotor seizures are more often missed or misdiagnosed compared with motor seizures, according to research presented in Neurology.

Dana-Farber Cancer Institute launched a neuro-inclusive oncology care and empowerment program designed to support adults with intellectual and/or developmental disabilities on their cancer journeys.

DENVER – A machine-learning seizure burden monitoring algorithm was able to predict the level of poor functional outcomes in those with neurological conditions, according to new research.

The FDA approved two new delivery methods of Xcopri for adults with partial-onset seizures, with the drug able to be crushed, mixed with water and administered by mouth as an oral suspension or via a nasogastric tube.

Vagus nerve stimulation surgeries were relatively safe, with complication rates low but differing depending on the type of procedure and presence of complications, researchers reported in Brain and Spine.

For childbearing aged women with idiopathic generalized epilepsy, switching medication from valproate to levetiracetam compared with lamotrigine decreased seizure recurrence at 24 months, according to research from Neurology.

Seizure frequency was reduced as much as 85% at 3 months in young patients with Dravet syndrome treated with a proprietary antisense oligonucleotide, according to results of phase 1/2a studies released by the manufacturer.

Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.

A biotherapeutics company has raised $120 million to advance its pipeline of cell therapies, including a lead investigational regenerative neural cell therapy candidate to treat drug-resistant mesial temporal lobe epilepsy.